Company intelligence / Profile preview

Lorantis

Cambridge, United Kingdom

Ownership: Private
Development stage: Other

Overview

Lorantis was a Cambridge-based biotechnology company specializing in the development of immunotherapeutics that modulate the Notch signaling pathway. The company's technology focused on inducing antigen-specific immune tolerance or activation to treat autoimmune diseases, allergies, and cancer. Its lead programs included therapies for graft-versus-host disease and various oncology indications. In 2005, Lorantis was acquired by Celldex Therapeutics to bolster Celldex's immunotherapy pipeline and platform. The acquisition integrated Lorantis's expertise in Notch signaling with Celldex's focus on targeted cancer therapies.

Therapeutic areas: OncologyImmunology
Modalities: Monoclonal antibodyRecombinant proteinProtein
Industry: Biotech

Beyond the preview

Go deeper on Lorantis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lorantis.

Explore the full profile